Grace Therapeutics, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements
Grace Therapeutics, Inc. (GRCE) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements of $241.00 thousand for the 12-month period ending 2026-03-31, per its 10-K filed 2026-06-18.
Financial Statements › Notes › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements · last filed 2026-06-18
- Grace Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2026-03-31 was $0.00.
- Grace Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2025-03-31 was $0.00.
- Grace Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2026 was $241.00K.
- Grace Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2025 was $0.00.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 12 month |
|---|---|---|---|
| 2026-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-18 | $241.00K 10-K · filed 2026-06-18 | |
| 2025-12-31 | $241.00K 10-Q · filed 2026-02-12 | ||
| 2025-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-18 | $0.00 10-K · filed 2026-06-18 | |
| 2024-12-31 | $0.00 10-Q · filed 2026-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |